ストックスクリーナーアプリを入手
987.05
0.18%
-1.82
プレマーケット:
987.61
0.56
+0.06%
Lilly Eli Co (LLY) 最新ニュース
Lilly grants Korean biotech 1STBIO access to proprietary AI drug discovery models - koreabiomed.com
Video: Blue Whale backs Eli Lilly's mass market appeal - Citywire
Narrow Tech Leadership Continues as Oil and Rates Fall - Investing.com
Eli Lilly (LLY) Reports Q1 2026 Revenue Surge of 56% Following FDA Approval of Foundayo - Insider Monkey
Lilly looks to sell about $8B of debt to fund acquisitions - Indianapolis Business Journal
Quarterly Sales Reach $8.7 Billion, Eli Lilly’s Mounjaro Becomes New Blockbuster Drug King - NAI500
Eli Lilly's Mounjaro overtakes Merck's Keytruda as world's top-selling drug - Business Standard
Change of leadership in the pharmaceutical world! Eli Lilly and Co's Mounjaro surpasses Merck & Co's Keytruda to become the world's best-selling drug. - 富途牛牛
Change of the top-selling drug! Eli Lilly and Co's Mounjaro surpasses Merck & Co's Keytruda to become the world's best-selling drug. - 富途牛牛
Lilly unveils new genetic medicine facility in Lebanon LEAP District and $4.5 billion investment - WFYI
Lilly’s Mounjaro overtakes Keytruda as world’s top-selling drug - The Boston Globe
Eli Lilly: Files for Eight Part Notes Offerin - Moomoo
Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence - Yahoo Finance
Top Research Reports for Eli Lilly, Western Digital & Vertiv - Yahoo Finance Singapore
[144] ELI LILLY & Co SEC Filing - Stock Titan
Eli Lilly Kicks Off High-Grade Bond Sale in Push to Fund Deals - Bloomberg.com
Lilly’s Mounjaro Overtakes ‘King Keytruda’ as World’s Top-Selling Drug - Bloomberg.com
Meet the minds behind CrossBridge Bio, Eli Lilly's $300M Houston buy - The Business Journals
Eli Lilly Opens First Dedicated Genetic Medicine Facility - Pharmaceutical Commerce
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits? - Yahoo Finance Singapore
Lilly Invests $4.5 Billion to Expand Indiana Manufacturing Sites - Bloomberg.com
Lilly pours $4.5B more into LEAP, as first facility opens in Lebanon - AOL.com
Eli Lilly commits additional $4.5B to Indiana manufacturing sites - WTHR
Lilly to invest additional $4.5 billion across Indiana manufacturing sites - WRTV
Lilly commits additional $4.5 billion in Indiana manufacturing sites - Reuters
Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions - Moomoo
Eli Lilly and Company announces additional $4.5 billion investment in 2 Lebanon sites - Fox 59
Eli Lilly (LLY) Stock: Lilly Is Building the Largest Drug Plant in U.S. History - CoinCentral
Lilly commits $4.5 billion to Indiana manufacturing expansion By Investing.com - Investing.com Canada
Lilly announces additional $4.5B investment at LEAP District manufacturing site - Inside INdiana Business
Lilly invests $4.5 billion to expand Indiana manufacturing sites - MSN
Novo Nordisk weight-loss pill powers profit beat in race to catch Eli Lilly - Reuters
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility - investor.lilly.com
Eli Lilly (LLY) files prospectus for multi‑series floating and fixed notes - Stock Titan
Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight - TechStock²
Novo Nordisk’s weight loss pill helps narrow gap with rival Lilly - whbl.com
Signal: Eli Lilly Stock Remains a "Buy" After Earnings - Schaeffer's Investment Research
Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch
Foundayo Liver Safety Questions Test Eli Lilly GLP-1 Growth Story - simplywall.st
Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show - 24/7 Wall St.
Are analysts too quick to gloss over Lilly’s liver case? - statnews.com
Eli Lilly Is Maintained at Overweight by Barclays - Moomoo
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,183 to $1,500 - 富途牛牛
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Icon (ICLR) - The Globe and Mail
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years - investor.lilly.com
Eli Lilly Stock (LLY) Opinions on Q1 Earnings and Foundayo Safety Report - Moomoo
3 Reasons It's Not Too Late to Buy Eli Lilly Stock - The Motley Fool
Eli Lilly and Co To Go Ex-Dividend On May 15th, 2026 With 1.73 USD Dividend Per Share - Moomoo
Is Eli Lilly stock heading for $1,000? - MSN
Eli Lilly Annual Meeting: Directors Win, Governance Changes Fail as Ricks Touts 45% Revenue Jump - Yahoo Finance
Is Eli Lilly Stock Heading for $1,000? - The Motley Fool
Eli Lilly (LLY) Faces Share Decline Amid Liver Failure Report Li - GuruFocus
Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125% - 24/7 Wall St.
Eli Lilly Recovers After Weight-Loss Patient Reports A Surprise Side Effect - Investor's Business Daily
Stock Quote & Chart | Eli Lilly and Company - investor.lilly.com
FDA Reports Liver Failure in Patient Taking Eli Lilly's Foundayo -- Barrons.com - 富途牛牛
Our Strongest Conviction Call: Eli Lilly Headed 21% Higher in 12 Months - 24/7 Wall St.
Eli Lilly (LLY) Responds to FDA Adverse Report on Foundayo - GuruFocus
The Most Surprising Thing About Eli Lilly's Impressive Revenue Growth: Just How Much More Potential There Is - AOL.com
Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lilly's dominance - CNBC
Eli Lilly and Company - Britannica
Eli Lilly’s (LLY) Weight Loss Pill is Better Than Novo’s, Says Jim Cramer - Insider Monkey
Eli Lilly declares $1.73 per share dividend for second quarter By Investing.com - Investing.com Australia
RBC Capital reiterates Eli Lilly stock rating on liver safety By Investing.com - Investing.com Canada
0.41%
2.03%
大文字化:
|
ボリューム (24 時間):